Full Press Release Details
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors.
IDYA
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors
Key Takeaway: IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors